Whole Pharmacogenomics Scan
Whole Pharmacogenomics Scan (WPSTM) is a comprehensive preemptive pharmacogenomics (PGx) testing offered by RPRD Diagnostics. It analyzes nearly 1,200 PGx genes in a single, one-time test.
Physicians can choose the gene/drug combinations for inclusion in the clinical report that provide the best value to their patients. We work closely with our customers to customize the clinical report and make adjustments, as needed, to best serve their practice.
WPS allows customers to incrementally build their precision medicine program by beginning with one or multiple medical conditions or focusing on a particular group of patients and then integrating additional gene/drug combinations into their prescribing decisions.
Read more about WPS testing and the WPS gene/drug pairs with clinical evidence.
WPS analyzes 4,627 markers in 1,191 genes of known PGx value. It includes most of the genes with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and CPIC levels. It covers nearly all genes and markers with PharmGKB clinical annotations.
Click here to search the WPS gene/drug pairs with CPIC level and view detailed description of genes with CPIC guideline.
Due to the large scope of the tests, the WPS gene/drug pair database only shows the genes/drugs that have CPIC level. If the genes you are searching for do not appear in our gene/drug database, please contact us or email to check if the genes are included in the WPS.
RPRD Diagnostics also specializes in developing custom panels using NGS and various genotyping technologies for our customers. If you are interested in creating a tailored panel, please contact us or email to discuss your project.
View more about our research experience and expertise in NGS.
WPS was developed from a highly comprehensive PGx assay (PharmacoScanTM)that analyzes 4,627 markers within nearly 1,200 genes1. It covers both common and rare variants, including copy number variations.
Click here to review the genes and alleles of the WPS testing.
Due to the large scope of the test, the haplotype/allele information will be added to the list in phases. If the genes or markers you are interested in are not shown in the list, please contact us or email firstname.lastname@example.org directly for more information.
RPRD uses PharmcoScanTM assay as a primary platform for genotyping and copy number variant (CNV) analysis for the WPS testing.
For clinical purpose, the typical turnaround time to receive patient results is 4-6 weeks from receipt of samples that meet specified requirements. Test results are reported Monday through Friday. If your project is for research purpose, please contact us to discuss your requirement for the turnaround time.
Targeted Panels (CNT and NT panels)-CEP72, NUDT15, and TPMT
CNT panels investigate all clinically relevant genetic variants of TPMT, NUDT15, and CEP72 to determine right therapies and appropriate dosing of thiopurines and vincristine in a single test. NT panels investigate all clinically relevant variants of NUDT15 and TPMT for thiopurine dosing. Single gene testing for NUDT15 or CEP72 is also available. Please contact us for more information.
Specific genetic variants in TPMT, NUDT15, and CEP72 that a patient carries determine his/her responses to thiopurines and vincristine. Compared to testing for a limited number of genetic variants, RPRD’s comprehensive CNT Panel or NT Panel reduces the likelihood of false prediction of toxicity risk. Therefore, it allows providers to more accurately determine the most effective dosing with the least toxicity for each patient. It is especially important to test comprehensive sets of genetic variants to accommodate diverse populations with higher likelihood of rare genotypes.
All patients who receive thiopurines and/or vincristine with concerns about toxicity should be tested. The latest CPIC guidelines recommend testing of both TPMT and NUDT15 to guide thiopurine dosing.
Yes. Testing for NUDT15 and TPMT only (NT panel) or single gene testing for NUDT15 or CEP72 is also available. Please contact us or email for more information.
RPRD Diagnostics utilizes real-time polymerase chain reaction (PCR) with fluorescence detection.
Please click here to see the typical turnaround time for clinical diagnostic testing. Test results are reported Monday through Friday. If your project is for research purpose, please contact us to discuss your requirement for the turnaround time.
View our lab accreditations to see our licenses and certifications.
All the tests for clinical diagnostic purposes need to be ordered by a licensed healthcare provider or a genetic counselor. Please review how to order tests for detailed ordering instructions. Specimen requirement and shipping instructions are provided in the test requisition form. Please contact us if you have any further questions.
If your samples are for research purposes only, you do not need to submit the test requisition form. Please contact us to discuss your research project.
RPRD offers its tests in the U.S. and in some international locations. Please contact us for more information on test availability in your area.
Please click here to see the specimen requirements for diagnostic testing.
If a specimen has previously been tested at RPRD, please contact us to inquire if sufficient DNA is still available for additional testing.
- Please send the samples to RPRD Diagnostics, LLC, 1225 Discovery Parkway, Ste 260, Milwaukee, WI 53226, USA.
- Specimens should be shipped Sunday through Thursday FedEx Priority Overnight or UPS Next Day Air. If a weekend delivery is necessary, please contact us to make special arrangements.
- Specimens must maintain ambient temperature during transport; we recommend insulated shipping containers. During hot weather, include a frozen ice pack in the shipping container. Specimens should not be allowed to freeze.
- Whole blood and saliva specimens must be received by RPRD Diagnostics within 7 days from time of collection to ensure specimen stability and quality.
- DOT and IATA requirements for proper shipping labels for biological substance, category B include:
- Placing specimen in a leak-proof secondary vessel.
- Place absorbent material between the primary and secondary packaging.
- An itemized list of contents must be enclosed between the secondary packaging and the outer packaging.
- Package and Air Waybill must show text: “biological substance, category B” and labeled with UN3373 designation.
- All delivery carriers (local and non-local) deliver directly to our office suite. We receive samples during our business hours: 7AM to 4PM CST.
- Holiday schedules will be posted on our webpage under, “how to order the test” at least one week prior to major holidays. Existing customers will also receive e-mail notifications of any schedule changes.
Please email us or call (414)-316-3097 with any questions.
Results and Reports
Contact us for a sample of the clinical report.
We work closely with our customers to customize their clinical report to provide the best value for their patients.
Yes, we work closely with our customers to create a customized clinical report that best aligns with their medical practice and make adjustments, as needed, as their teams and practices evolve.
Email us or call at (414)-316-3097.
RPRD offers three payment options: institutional billing, insurance billing and patient self-pay.
Please email us if you need further assistance.
Yes, RPRD offers direct-to-payer billing services. Please email us for more details.
Please click here to see the CPT codes.
Yes, please contact us or call +1 (414)-316-3097 for more information.
Please email us or call +1 (414)-316-3097 with additional questions.
Please email or call +1 (414)-316-3097 for any questions related to the clinical report.
Please email or call (414)-316-3097 for any additional technical questions.
If you have a question that isn’t answered above, please contact us.